E. Eisenhauer - Concepedia

Author

E. Eisenhauer

Ottawa Regional Cancer Foundation

Also Known As

E A Eisenhauer, E Eisenhauer, E. A. Eisenhauer, E. Eisenhauer, E.A. Eisenhauer, EA Eisenhauer

Publications

31.1K

Citations

H-Index

Concepts

All Affiliations

Ottawa Regional Cancer Foundation Ontario Institute for Cancer Research BC Cancer Agency European Organisation for Research and Treatment of Cancer Princess Margaret Cancer Centre

About

E. Eisenhauer is an author at Ottawa Regional Cancer Foundation specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	29	29.9K
2	Health Sciences	12	12	29.3K
3	Immunology	4	4	97
4	Arts	1	1	113
5	Cell Biology	1	1	76

E. Eisenhauer

Publications

30.4K

Citations

H-Index

Page 1

	Year	Citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. Eisenhauer, P. Therasse, Jan Bogaerts, European Journal of Cancer Surgical OncologyRecist GuidelineMedicineCancer ManagementSolid Tumours	2008	28.6K
Evaluation of lymph nodes with RECIST 1.1 Lawrence H. Schwartz, Jan Bogaerts, Robert Ford, European Journal of Cancer Medical ImagingMedicineRecist 1.1HistopathologyLymphatic System	2008	288
Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC) Yvon Cormier, E. Eisenhauer, A. Muldal, Annals of Oncology MedicinePharmacologyActive New AgentAnti-cancer AgentCancer Treatment	1994	146
Speeding up the Evaluation of New Agents in Cancer Mahesh Parmar, F. M.- S. Barthel, Matthew R. Sydes, JNCI Journal of the National Cancer Institute New AgentsCancer ManagementClinical EndpointSurgeryTumor Biology	2008	139
Successful re-treatment with taxol after major hypersensitivity reactions. David M. Peereboom, Ross C. Donehower, E. Eisenhauer, Journal of Clinical Oncology	1993	113
Lessons learned from independent central review Robert Ford, Lawrence H. Schwartz, Janet Dancey, European Journal of Cancer ReliabilityBiasQuality ReviewArtsJournalism	2008	113
Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. D Perrault, E. Eisenhauer, K. I. Pritchard, Journal of Clinical Oncology	1996	96
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial Meg Knowling, Martin E. Blackstein, Richard Tozer, Investigational New Drugs National Cancer InstituteMalignant DiseaseMedicineMetronomic TherapyPhase Ii Study	2006	83
Carboplatin versus cisplatin Jan B. Vermorken, W.W. ten Bokkel Huinink, E. Eisenhauer, Annals of Oncology ChromatinCarboplatin Versus CisplatinMedicineAnti-cancer AgentCancer Treatment	1993	76
Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG Jacobus Pfisterer, Marie Plante, Ignace Vergote, Journal of Clinical Oncology Cancer ManagementGynecologyPharmacotherapyGynecology OncologyOvarian Cancer	2004	60

Page 1